MX2023010457A - Formulacion de proteina de fusion que incluye el dominio extracelular de la subunidad alfa del receptor fc de ige. - Google Patents
Formulacion de proteina de fusion que incluye el dominio extracelular de la subunidad alfa del receptor fc de ige.Info
- Publication number
- MX2023010457A MX2023010457A MX2023010457A MX2023010457A MX2023010457A MX 2023010457 A MX2023010457 A MX 2023010457A MX 2023010457 A MX2023010457 A MX 2023010457A MX 2023010457 A MX2023010457 A MX 2023010457A MX 2023010457 A MX2023010457 A MX 2023010457A
- Authority
- MX
- Mexico
- Prior art keywords
- ige
- fusion protein
- receptor
- formulation
- extracellular domain
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 102000009109 Fc receptors Human genes 0.000 title abstract 3
- 108010087819 Fc receptors Proteins 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000013636 protein dimer Substances 0.000 abstract 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001993 poloxamer 188 Polymers 0.000 abstract 1
- 229940044519 poloxamer 188 Drugs 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a una formulación optimizada por un dímero de proteína de fusión que comprende un dominio extracelular de una subunidad alfa de un receptor de IgE. Específicamente, la presente invención se refiere a una formulación farmacéutica acuosa que comprende un dímero de proteína de fusión que comprende un dominio extracelular de una subunidad alfa de un receptor Fc de IgE, histidina, prolina, metionina, y poloxámero 188, en donde el pH de la formulación es desde 6.0 a 7.0. La proteína de fusión presente en la formulación de conformidad con la presente invención está incluida en una alta concentración, tiene una estabilidad mejorada, puede administrarse convenientemente mediante inyección subcutánea y tiene una excelente capacidad de unión a IgE en comparación con un agente terapéutico convencional que comprende un anticuerpo anti-IgE. De este modo, puede utilizarse de forma útil como inyección para el tratamiento de enfermedades alérgicas mediadas por IgE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210030501 | 2021-03-09 | ||
| PCT/KR2022/003207 WO2022191550A1 (ko) | 2021-03-09 | 2022-03-07 | ＩｇＥ Ｆｃ 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010457A true MX2023010457A (es) | 2023-09-14 |
Family
ID=83227989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010457A MX2023010457A (es) | 2021-03-09 | 2022-03-07 | Formulacion de proteina de fusion que incluye el dominio extracelular de la subunidad alfa del receptor fc de ige. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240148829A1 (es) |
| EP (1) | EP4306103A1 (es) |
| JP (1) | JP2024509937A (es) |
| KR (1) | KR20220126654A (es) |
| CN (1) | CN116963721A (es) |
| AU (1) | AU2022232566A1 (es) |
| CA (1) | CA3211978A1 (es) |
| CL (1) | CL2023001670A1 (es) |
| IL (1) | IL305512A (es) |
| MX (1) | MX2023010457A (es) |
| PE (1) | PE20240120A1 (es) |
| TW (1) | TW202302138A (es) |
| WO (1) | WO2022191550A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2415604T3 (es) | 2007-05-30 | 2013-07-26 | Postech Academy-Industry- Foundation | Proteínas de fusión de inmunoglobulina |
| EP2331578B1 (en) | 2008-09-17 | 2014-06-04 | Xencor, Inc. | Novel compositions and methods for treating ige-mediated disorders |
| US20120294866A1 (en) * | 2010-01-19 | 2012-11-22 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for proteins |
| WO2019135666A1 (ko) * | 2018-01-08 | 2019-07-11 | 주식회사 프로젠 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
| SG11202005858WA (en) | 2018-01-08 | 2020-07-29 | Gi Innovation Inc | Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same |
| KR20200125590A (ko) * | 2018-01-26 | 2020-11-04 | 제넨테크, 인크. | 조성물 및 사용 방법 |
| EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
-
2022
- 2022-03-07 MX MX2023010457A patent/MX2023010457A/es unknown
- 2022-03-07 AU AU2022232566A patent/AU2022232566A1/en active Pending
- 2022-03-07 CN CN202280016419.9A patent/CN116963721A/zh active Pending
- 2022-03-07 EP EP22767446.2A patent/EP4306103A1/en active Pending
- 2022-03-07 JP JP2023555346A patent/JP2024509937A/ja active Pending
- 2022-03-07 KR KR1020220028919A patent/KR20220126654A/ko unknown
- 2022-03-07 WO PCT/KR2022/003207 patent/WO2022191550A1/ko active Application Filing
- 2022-03-07 CA CA3211978A patent/CA3211978A1/en active Pending
- 2022-03-07 PE PE2023002481A patent/PE20240120A1/es unknown
- 2022-03-07 US US18/549,558 patent/US20240148829A1/en active Pending
- 2022-03-08 TW TW111108408A patent/TW202302138A/zh unknown
- 2022-03-09 IL IL305512A patent/IL305512A/en unknown
-
2023
- 2023-06-08 CL CL2023001670A patent/CL2023001670A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL305512A (en) | 2023-10-01 |
| AU2022232566A1 (en) | 2023-08-03 |
| JP2024509937A (ja) | 2024-03-05 |
| EP4306103A1 (en) | 2024-01-17 |
| US20240148829A1 (en) | 2024-05-09 |
| CA3211978A1 (en) | 2022-09-15 |
| CN116963721A (zh) | 2023-10-27 |
| CL2023001670A1 (es) | 2023-11-24 |
| PE20240120A1 (es) | 2024-01-22 |
| AU2022232566A9 (en) | 2024-05-16 |
| KR20220126654A (ko) | 2022-09-16 |
| WO2022191550A1 (ko) | 2022-09-15 |
| TW202302138A (zh) | 2023-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7245649B2 (ja) | 眼疾患を治療するためのアディポネクチンペプチド模倣薬（関連出願の相互参照） | |
| EA200800050A1 (ru) | Самобуферирующиеся композиции белков | |
| CN112533676A (zh) | 用于抑制cgrp的神经毒素 | |
| TW200526209A (en) | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions | |
| EA201391739A1 (ru) | Стабильная жидкая композиция этанерцепта | |
| PE20050190A1 (es) | Formulacion de inmunoglobulina y metodo de preparacion de la misma | |
| PE20050394A1 (es) | FORMULACIONES DE ANTICUERPO MONOCLONAL anti-lge ALTAMENTE CONCENTRADO | |
| RU2016129953A (ru) | Фармацевтические комбинации | |
| AR074357A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| US20200121675A1 (en) | A topical composition for treating rosacea and a method for treating rosacea with the same | |
| PT1401413E (pt) | Uso de inibidores da tirosina cinase para tratar doenças alérgicas | |
| MX2023010457A (es) | Formulacion de proteina de fusion que incluye el dominio extracelular de la subunidad alfa del receptor fc de ige. | |
| FI3672631T3 (fi) | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia | |
| ES2908141T3 (es) | Formulaciones y dosis de cannabinoides | |
| US20030223949A1 (en) | Use of a polypeptide for treatment of pruritus in animals | |
| AU2014256510B2 (en) | Highly concentrated formulations of soluble Fc receptors | |
| CN101795670A (zh) | G-csf的液体制剂 | |
| JP6453318B2 (ja) | 委縮性皮膚瘢痕を治療するためのプロスタグランジンＦ２α及びその類似体 | |
| ES2930757T3 (es) | Una formulación de fármaco para uso en el control eficaz del dolor agudo y/o crónico | |
| US10004734B2 (en) | Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists | |
| US8314118B2 (en) | Methods and compositions for treating dry eye | |
| JP5767759B1 (ja) | ヘパリン含有組成物 | |
| JP7278503B2 (ja) | コンシズマブの医薬製剤およびその生産方法 | |
| CA3239501A1 (en) | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions |